<DOC>
	<DOCNO>NCT01771146</DOCNO>
	<brief_summary>A prospective evaluation neoadjuvant FOLFIRINOX regimen patient non-metastatic pancreas cancer ( Baylor University Medical Center Texas Oncology Experience )</brief_summary>
	<brief_title>Neoadjuvant FOLFIRINOX Regimen Patients With Non-metastatic Pancrease Cancer</brief_title>
	<detailed_description>Patients pancreas cancer enrol treat planned course 6 cycle ( 3 month ) chemotherapy FOLFIRINOX prior undergo surgical resection .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Pancrelipase</mesh_term>
	<mesh_term>Pancreatin</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<criteria>18 year age old Male nonpregnant nonlactating female Histologically cytologically confirm adenocarcinoma pancreas Patients must satisfactory blood count blood chemistry level baseline ( refer Appendix 2 , Study Laboratory References Range ) . Patient Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 1 ( refer Appendix 7 ) : 0 Asymptomatic ( Fully active , able carry predisease activity without restriction ) 1 Symptomatic completely ambulatory ( Restricted physically strenuous activity ambulatory able carry work light sedentary nature . For example , light housework , office work ) Signed study consent form &lt; 18 year age Pregnant lactate female Patient islet cell neoplasms Patient known brain metastasis Patient metastatic disease Active secondary malignancy Active , uncontrolled bacterial , viral , fungal infection ( ) require systemic therapy Known infection hepatitis B , hepatitis C , cirrhosis Major surgery vascular device placement ( exclude port IV medication/chemotherapy ) within 2 week prior Day 1 treatment study Prior chemotherapy radiation pancreatic cancer History allergy hypersensitivity study drug Patient enrol outside ( outside Baylor University Medical Center Texas Oncology ) clinical protocol investigational trial Significant cardiac disease define New York Heart Association ( NYHA ) classification III IV , uncontrolled congestive heart failure ( CHF ) , prior myocardial infarction ( MI ) last 6months Any prior gastrointestinal ( GI ) disease history prior pelvic abdominal radiation opinion investigator may place patient increase risk Peripheral sensory neuropathy â‰¥ grade 2 baseline Significant comorbidities deem investigator unsuitable participation/enrollment Study consent form sign</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Non-metastatic Pancreas Cancer</keyword>
	<keyword>Pancreatic Cancer</keyword>
	<keyword>Cancer Pancreas</keyword>
	<keyword>Adenocarcinoma Pancreas</keyword>
	<keyword>Neoadjuvant</keyword>
</DOC>